Evidence map›Paper›PMID 41880731›Full record

ArticleJACC. Basic to translational science2026

eNOS Uncoupling-ER Stress-Mitochondrial Dysfunction Axis in the Development of Pulmonary Hypertension.

Priya Murugesan, Yunxia Zhang, Meng Zhang, Yixuan Zhang, Hua Cai

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JACC. Basic to translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Hypertensive mt. tRNARedox biology · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Priya MurugesanDivision of Molecular Medicine, Department of Anesthesiology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, USA; Division of Cardiology, Department of Medicine, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, USA.
Yunxia Zhangthe Department of Pulmonary Medicine, Capital Medical University, Beijing, China.
Meng Zhangthe Department of Pulmonary Medicine, Capital Medical University, Beijing, China.
Yixuan ZhangDivision of Molecular Medicine, Department of Anesthesiology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, USA; Division of Cardiology, Department of Medicine, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, USA.
Hua CaiDivision of Molecular Medicine, Department of Anesthesiology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, USA; Division of Cardiology, Department of Medicine, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, USA. Electronic address: hcai@mednet.ucla.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pulmonary hypertension (PH) was induced by 2,4-diamino 6-hydroxypyrimidine or hypoxia exposure. Remarkably, folic acid (attenuating endothelial nitric oxide synthase [eNOS] uncoupling) or phenylbutyric acid (abrogating endoplasmic reticulum stress) markedly alleviated mean pulmonary arterial pressure /right ventricular systolic pressure, vascular remodeling, total and mitochondrial superoxide production, and eNOS uncoupling, while preserving NO bioavailability. MitoTempo to scavenge mitochondrial reactive oxygen species abolished molecular and pathophysiological features of PH. Folic acid, phenylbutyric acid, or combination attenuated mitochondrial swelling and distortion of mitochondrial cristae. Using 2,4-diamino 6-hydroxypyrimidine increased total and mitochondrial superoxide production in pulmonary artery endothelial cells. Our data for the first time establish a novel eNOS uncoupling/endoplasmic reticulum stress/mitochondrial dysfunction signaling axis in mediating PH, which are targetable for novel therapeutics.

Indexed as

2,4-diamino 6-hydroxypyrimidine (DAHP)dihydrofolate reductaseendothelial dysfunctioneNOS uncouplingER stresshypoxiamitochondrial dysfunctionpulmonary hypertensionvascular remodeling

Identifiers

PMID41880731
PMCPMC13053695

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.